Sanna G, Meoli P, Bianchini C, Rovelli F
G Ital Cardiol. 1983;13(3):145-51.
A randomized double-blind cross-over trial was carried out in 20 patients suffering from ventricular ectopic contractions (VECs), in order to evaluate the effectiveness of a new antiarrhythmic drug, Propafenone (P), versus Lorajmine (L). The patients were given 900 mg/day P and 600 mg/day L in three divided doses for 3 days. Every patient was evaluated with four 24-hour ambulatory ECGs, the first at the beginning of the trial, the second after the administration of the first drug, the third after the administration of the second drug and the last after wash-out. With P, the average fall in VECs was 70.6 +/- 10.8% with a clinically significant individual response in 14 of the 20 patients (VECs reduction greater than or equal to 75%, VECs mean decrease: 93.5 +/- 2.1%). With L, VECs decreased by 37.4 +/- 14.2% whilst VECs reduction was larger than 75% only in 50% patients (VECs mean decrease 85.8 +/- 3.1%). Lastly, after therapy interruption, VECs globally increased by +5.4 +/- 14.4%. Propafenone is a considerably active drug against ventricular arrhythmias. It proved to be more effective than Lorajmine under our experimental conditions.
对20例室性早搏（VECs）患者进行了一项随机双盲交叉试验，以评估一种新型抗心律失常药物普罗帕酮（P）与劳拉西敏（L）的疗效。患者按每日900mg的剂量分三次服用P，按每日600mg的剂量分三次服用L，持续3天。每位患者均接受4次24小时动态心电图检查，第一次在试验开始时，第二次在服用第一种药物后，第三次在服用第二种药物后，最后一次在洗脱期后。服用P后，VECs平均下降70.6±10.8%，20例患者中有14例出现具有临床意义的个体反应（VECs减少大于或等于75%，VECs平均下降：93.5±2.1%）。服用L后，VECs下降了37.4±14.2%，而只有50%的患者VECs减少大于75%（VECs平均下降85.8±3.1%）。最后，在治疗中断后，VECs总体增加了+5.4±14.4%。普罗帕酮是一种对室性心律失常相当有效的药物。在我们的实验条件下，它被证明比劳拉西敏更有效。
